Close Menu

Alnylam and Medtronic are working together to develop RNA interference as a treatment for Huntington's disease, reports The Wall Street Journal. Medtronic is working the task of creating a pump and catheter system to deliver Alnylam's therapy to the right spot of the brain "without hiking up cranial pressure too much and damaging brain tissue," the Journal adds. Alnylam is using an siRNA to block mRNA.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.